Vaccine AIDS Colon Cancer Patients
Posted on: Thursday, 16 November 2006, 00:00 CST
A vaccine developed in the U.K. stimulated the production of killer T cells in up to 70 of colorectal cancer patients.
Researchers at the University of Nottingham cloned an antibody called 105AD7 from a patient with colorectal cancer who survived seven years with liver metastases.
The study involved 67 patients, average age 66, with colorectal cancer of varying severity. They were randomized to receive 100 mcg of 105AD7, 105AD7 with BCG (a bacteria used to stimulate the immune system in cancer patients) during the first immunization followed by 105AD7 alone, or no treatment.
Around 70 percent of patients responded to the vaccine, which increased the production of an immune system protein called TNF-alpha. TNF-alpha stimulated the production of killer T cells, which produced cancer-destroying immune proteins called cytokines. Survival rates were not studied.
The study appears in the November 15 issue of Clinical Cancer Research.
Source: United Press International
Related Articles
- Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program
- Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
- Delaware Cancer Patients Among Nation's First to Benefit From Expansion of the American Cancer Society's 'Patient Navigator Program'
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Argos Therapeutics Initiates Phase I/II Trial With AGS-003 Personalized Immunotherapy in Advanced Kidney Cancer; Trial to Evaluate New Production Process That May Yield More Potent Immune Response
- Aggressive Immune Response Helps Colorectal Cancer Patients
- Two New, Cancer-Fighting TeaForHealth Green Tea Products, Presentation of ''The Science of Tea As Medicine'' and Q&A on FDA Qualified Health Claim for Green Tea
- Narrative Review: Screening for Colorectal Cancer in Patients With a First-Degree Relative With Colonic Neoplasia
 |
 |
User Comments (0)
RSS Feeds